Why Neuland Laboratories shares fall 7% in trade? check reasons here

As per reports, Smallcap World Fund was planning to sell a 3.8 percent stake in the Neuland Laboratories through a block deal

Market, BSE, NSE, NIfty, Stock Market, investment, Loss, Lost
SI Reporter Mumbai
2 min read Last Updated : Dec 12 2024 | 2:02 PM IST
Neuland Laboratories shares lost 7.2 per cent in trade on Thursday and logged an intraday low of Rs 15,725 per share on BSE. Around 9:59 AM, 0.705 million shares changed hands on the National Stock Exchange (NSE) and 0.01 million shares changed hands on the BSE. 
 
Meanwhile, Neuland Laboratories Ltd. share price was down 4.09 per cent at Rs 16,256.25 per share on BSE. In comparison, BSE Sensex was up 0.04 per cent at 81,555.79. The market capitalisation of the company stood at Rs 20,856.59 crore. The 52-week high of the stock was at Rs 18,089.55 per share and 52-week low of the stock stood at Rs 4,928 per share.
 
As per reports, Smallcap World Fund was planning to sell a 3.8 percent stake in the Neuland Laboratories through a block deal. In the quarter that ended September 30, 2024, Smallcap World Fund held a 3.77 per cent stake in the company, as per BSE shareholding data. 
 
That apart, individual investor Mukul Agarwal also held a 3.12 per cent stake in the company along with Siddharth Iyer, who holds a 1.69 per cent, stake in the the company as of September 30, 2024.
 
Neuland Laboratories, established in 1984 and headquartered in Hyderabad, India, is a pharmaceutical company specialising in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), Custom Manufacturing Solutions (CMS), and complex specialty APIs. 
 
These include high-potency APIs and complex molecules, developed with advanced synthesis techniques and compliant with global regulatory standards.
 
Neuland provides services such as custom chemical synthesis, peptide synthesis, and process optimisation for pharmaceutical companies.
 
The company caters to a wide range of therapeutic areas, including central nervous system disorders, cardiovascular diseases, and oncology, using advanced synthesis techniques and adhering to stringent global regulatory standards.
 
In the past one year, Neuland Laboratories shares have gained 236 per cent against Sensex's rise of 17 per cent. 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Neuland LaboratoriesBuzzing stocksstock market tradingBSE SensexNSE NiftyMarkets Sensex NiftyMARKETS TODAY

First Published: Dec 12 2024 | 10:18 AM IST

Next Story